A Phase 1 interventional study of Depemokimab in Asthma, sponsored by GlaxoSmithKline. Completed at 3 sites in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing depemokimab in Asthma — 3 open to participants now, 3 under way, 3 of them phase 3. depemokimab · Asthma.
Among the 10 studies testing depemokimab in Asthma, this one is the 7th largest by enrollment, is one of 2 that started in 2022, is one of 3 in phase 1, and was the 7th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →3 of the 10 studies testing depemokimab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States
Ages 6–11
GlaxoSmithKline · Sites in United States, United Kingdom
Ages 12+
GlaxoSmithKline · Sites in United States, Belgium, Canada and 9 more countries
Ages 18+
By country, each count listing its studies:
depemokimab: first FDA approval 2025 (EXDENSUR), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 2 started in 2022.
This study's enrollment of 140 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 273 across the 10 interventional studies. Of the 7 that completed or were terminated, 7 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 1 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 106th largest by enrollment of the 238 interventional ones that give a count, is one of 2 that started in 2022, is one of 62 in phase 1, and was the 243rd registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
1 of the studies testing depemokimab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07671001Phase 3GlaxoSmithKlineA Study of Depemokimab in Participants of 6 to 11 Years of Age | 2027-03-01 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing depemokimab in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
This study will compare the pharmacokinetics, safety, tolerability, and immunogenicity of Depemokimab administered via a SSD or autoinjector in healthy participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single subcutaneous dose of 100 milligrams (mg) of depemokimab administered via a Safety Syringe Device (SSD) on Day 1.
Biological: Depemokimab
Participants received a single subcutaneous dose of 100 mg of depemokimab administered via an autoinjector on Day 1.
Biological: Depemokimab
Depemokimab was administered via SSD or autoinjector.
Maximum Observed Plasma Concentration (Cmax) of Depemokimab
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.
Time frame: Day 1: Pre-dose and 2, 8 hours post-dose; Days 2, 3, 5, 8, 15, 29, 57, 85, 127, 169 and 183 post-dose
Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC[0-inf]) of Depemokimab
Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.
Time frame: Day 1: Pre-dose and 2, 8 hours post-dose; Days 2, 3, 5, 8, 15, 29, 57, 85, 127, 169 and 183 post-dose
Area Under the Concentration-time Curve From Time Zero to Time of Last Observed Quantifiable Concentration (AUC[0-t]) of Depemokimab
Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.
Time frame: Day 1: Pre-dose and 2, 8 hours post-dose; Days 2, 3, 5, 8, 15, 29, 57, 85, 127, 169 and 183 post-dose
Time to Maximum Observed Plasma Concentration (Tmax) of Depemokimab
Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.
Time frame: Day 1: Pre-dose and 2, 8 hours post-dose; Days 2, 3, 5, 8, 15, 29, 57, 85, 127, 169 and 183 post-dose
Apparent Clearance Following Extravascular Administration (CL/F) of Depemokimab
Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.
Time frame: Day 1: Pre-dose and 2, 8 hours post-dose; Days 2, 3, 5, 8, 15, 29, 57, 85, 127, 169 and 183 post-dose
Apparent Volume of Distribution Following Extravascular Administration (Vd/F) of Depemokimab
Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.
Time frame: Day 1: Pre-dose and 2, 8 hours post-dose; Days 2, 3, 5, 8, 15, 29, 57, 85, 127, 169 and 183 post-dose
Terminal Elimination Rate Constant (Lambda z) of Depemokimab
Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.
Time frame: Day 1: Pre-dose and 2, 8 hours post-dose; Days 2, 3, 5, 8, 15, 29, 57, 85, 127, 169 and 183 post-dose
Terminal Elimination Half-Life (T1/2) Following Administration of Depemokimab
Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.
Time frame: Day 1: Pre-dose and 2, 8 hours post-dose; Days 2, 3, 5, 8, 15, 29, 57, 85, 127, 169 and 183 post-dose
Time of Last Measurable Plasma Concentrations (Tlast) of Depemokimab
Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.
Time frame: Day 1: Pre-dose and 2, 8 hours post-dose; Days 2, 3, 5, 8, 15, 29, 57, 85, 127, 169 and 183 post-dose
Percentage of AUC (0-Inf) Due to Extrapolation From the Time of the Last Observed Concentration (Tlast) to Infinity (%AUCex) of Depemokimab
Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods. The percentage of AUC (0-inf) obtained by extrapolation (%AUCex) was calculated as: (AUC\[0-inf\] - AUC\[0-t\]) /AUC(0-inf)\*100.
Time frame: Day 1: Pre-dose and 2, 8 hours post-dose; Days 2, 3, 5, 8, 15, 29, 57, 85, 127, 169 and 183 post-dose
Number of Participants With Presence of Positive Anti-depemokimab Antibodies
Blood samples were collected and analyzed for the presence of anti- depemokimab antibodies using a validated immunoassay. The assay involved screening, confirmation and titration steps. If serum samples tested positive in the screening assay, they were considered 'potentially positive' and were further analyzed for the specificity using the confirmation assay. Samples that confirmed positive in the confirmation assay were reported as 'positive'. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1), Weeks 4, 8, 12 and 26
Number of Participants With Positive Neutralizing Antibodies to Depemokimab
Blood samples were collected for determination of positive neutralizing antibodies. A neutralizing antibody assay was performed. Neutralizing antibody test was only carried out for participants who have had a positive confirmatory binding antibody test result at visit. A participant was considered positive if they had at least one positive post-Baseline neutralizing antibody result. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1), Weeks 4, 8, 12 and 26
This was a single-dose study in healthy adult participants to compare the pharmacokinetics of depemokimab when delivered with a Safety Syringe Device (SSD) or an Autoinjector.
| Milestone | Depemokimab Via SSD | Depemokimab Via Autoinjector |
|---|---|---|
| Started | 70 | 70 |
| Completed | 69 | 69 |
| Not completed | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.
| Micrograms per milliliter | Depemokimab Via SSD | Depemokimab Via Autoinjector |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Depemokimab | 14.68 ± 24.17 | 14.97 ± 23.29 |
Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.
| Day*microgram/mL | Depemokimab Via SSD | Depemokimab Via Autoinjector |
|---|---|---|
| Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC[0-inf]) of Depemokimab | 1061.05 ± 26.89 | 1078.66 ± 28.39 |
Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.
| Day*microgram/mL | Depemokimab Via SSD | Depemokimab Via Autoinjector |
|---|---|---|
| Area Under the Concentration-time Curve From Time Zero to Time of Last Observed Quantifiable Concentration (AUC[0-t]) of Depemokimab | 999.38 ± 26.07 | 1014.29 ± 27.35 |
Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.
| Day | Depemokimab Via SSD | Depemokimab Via Autoinjector |
|---|---|---|
| Time to Maximum Observed Plasma Concentration (Tmax) of Depemokimab | 12.97 (4.0 to 28.9) | 12.43 (3.9 to 28.0) |
Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.
| Liters/day | Depemokimab Via SSD | Depemokimab Via Autoinjector |
|---|---|---|
| Apparent Clearance Following Extravascular Administration (CL/F) of Depemokimab | 0.09 ± 26.89 | 0.09 ± 28.39 |
Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.
| Liters | Depemokimab Via SSD | Depemokimab Via Autoinjector |
|---|---|---|
| Apparent Volume of Distribution Following Extravascular Administration (Vd/F) of Depemokimab | 5.64 ± 25.02 | 5.51 ± 27.23 |
Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.
| Per day | Depemokimab Via SSD | Depemokimab Via Autoinjector |
|---|---|---|
| Terminal Elimination Rate Constant (Lambda z) of Depemokimab | 0.02 ± 24.46 | 0.02 ± 23.49 |
Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.
| Day | Depemokimab Via SSD | Depemokimab Via Autoinjector |
|---|---|---|
| Terminal Elimination Half-Life (T1/2) Following Administration of Depemokimab | 41.45 ± 24.46 | 41.19 ± 23.49 |
Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.
| Day | Depemokimab Via SSD | Depemokimab Via Autoinjector |
|---|---|---|
| Time of Last Measurable Plasma Concentrations (Tlast) of Depemokimab | 179.21 ± 13.510 | 177.74 ± 16.385 |
Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods. The percentage of AUC (0-inf) obtained by extrapolation (%AUCex) was calculated as: (AUC\[0-inf\] - AUC\[0-t\]) /AUC(0-inf)\*100.
| Percentage of AUC extrapolation | Depemokimab Via SSD | Depemokimab Via Autoinjector |
|---|---|---|
| Percentage of AUC (0-Inf) Due to Extrapolation From the Time of the Last Observed Concentration (Tlast) to Infinity (%AUCex) of Depemokimab | 5.02 ± 73.24 | 5.06 ± 64.04 |
Blood samples were collected and analyzed for the presence of anti- depemokimab antibodies using a validated immunoassay. The assay involved screening, confirmation and titration steps. If serum samples tested positive in the screening assay, they were considered 'potentially positive' and were further analyzed for the specificity using the confirmation assay. Samples that confirmed positive in the confirmation assay were reported as 'positive'. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Participants | Depemokimab Via SSD | Depemokimab Via Autoinjector |
|---|---|---|
| Baseline (Day 1) | 1 | 0 |
| Week 4 | 1 | 0 |
| Week 8 | 1 | 0 |
| Week 12 | 1 | 0 |
| Week 26 | 2 | 1 |
Blood samples were collected for determination of positive neutralizing antibodies. A neutralizing antibody assay was performed. Neutralizing antibody test was only carried out for participants who have had a positive confirmatory binding antibody test result at visit. A participant was considered positive if they had at least one positive post-Baseline neutralizing antibody result. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Participants | Depemokimab Via SSD | Depemokimab Via Autoinjector |
|---|---|---|
| Baseline (Day 1) | 1 | — |
| Week 4 | 1 | — |
| Week 8 | 1 | — |
| Week 12 | 1 | — |
| Week 26 | 1 | 1 |
Collected over All-cause mortality, serious adverse events (SAEs) and common greater than equal to (>=) 3 percent (%) non-serious adverse events (Non-SAEs) were collected up to 211 days. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Depemokimab Via SSD | 0/70 (0%) | 0/70 (0%) | 16/70 (22.9%) |
| Depemokimab Via Autoinjector | 0/70 (0%) | 2/70 (2.9%) | 24/70 (34.3%) |
| Event | Depemokimab Via SSD | Depemokimab Via Autoinjector |
|---|---|---|
| Pelvic inflammatory diseaseInfections and infestations | 0/70 | 1/70 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/70 | 1/70 |
| Event | Depemokimab Via SSD | Depemokimab Via Autoinjector |
|---|---|---|
| HeadacheNervous system disorders | 7/70 | 6/70 |
| Injection site swellingGeneral disorders | 1/70 | 4/70 |
| Abdominal painGastrointestinal disorders | 1/70 | 3/70 |
| DiarrhoeaGastrointestinal disorders | 1/70 | 3/70 |
| NauseaGastrointestinal disorders | 3/70 | 1/70 |
| VomitingGastrointestinal disorders | 3/70 | 1/70 |
| Injection site bruisingGeneral disorders | 3/70 | 1/70 |
| Injection site erythemaGeneral disorders | 2/70 | 3/70 |
| COVID-19Infections and infestations | 2/70 | 3/70 |
| Viral upper respiratory tract infectionInfections and infestations | 0/70 | 3/70 |
| Age, Continuous(YEARS) | Depemokimab Via SSD | Depemokimab Via Autoinjector | Total |
|---|---|---|---|
| Mean | 36.2 ± 7.76 | 34.8 ± 8.25 | 35.5 ± 8.01 |
| Sex: Female, Male(Participants) | Depemokimab Via SSD | Depemokimab Via Autoinjector | Total |
|---|---|---|---|
| Female | 35 | 40 | 75 |
| Male | 35 | 30 | 65 |
| Race/Ethnicity, Customized(Participants) | Depemokimab Via SSD | Depemokimab Via Autoinjector | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 3 | 4 | 7 |
| Black or African American | 15 | 22 | 37 |
| White | 45 | 43 | 88 |
| Mixed Race | 6 | 1 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
Ran from Dec 2022 to primary completion in Oct 2023, 10 months.
Results were first posted in Jun 2026, 2 years 7 months after primary completion.
Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 10 months is above that.
Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Depemokimab